GAIA BioMedicine Closes JPY 1.3 Billion (USD 11.9 Million) Series B Investment to Advance the GAIA-102 Platform, The Panted “Off-The-Shelf” NK Cells Like Cell Therapy Platform, For Versatile Solid Tumors

GAIA BioMedicine Inc., a leading biotechnology company in Japan developing its proprietary NK-cell-like cells “GAIA-102”, announced that it had closed a JPY 1.3 billion Series B financing (including an upfront for collaborative research from one of the existing shareholders). In addition to receiving funds from existing investors of the Series A round, prominent biotech-focused venture capitals and public strategic corporations participated in the funding, including Osaka University Venture Capital, SBI Investment Co., Ltd., Hisamitsu Pharmaceutical Co., Inc. and CEJ Fund (operated by CEJ Capital, Inc., a subsidiary of Cyberdyne, Inc.)  

The financing will support clinical trials targeting solid tumors, including NSCLCs, and expedite the development of the GAIA-102 platform.